- Home
- CROX vs RYTM Comparison
CROX vs RYTM Comparison
Compare CROX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CROX | RYTM |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.8B |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CROX | RYTM |
|---|---|---|
| Price | $125.87 | $96.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $99.90 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.2M | 652.4K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $4,040,647,000.00 | N/A |
| Revenue This Year | $2.01 | $55.34 |
| Revenue Next Year | $2.60 | $86.06 |
| P/E Ratio | $46.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $73.21 | $62.29 |
| 52 Week High | $129.79 | $122.20 |
Technical Indicators
Market Signals| Indicator | CROX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 64.40 |
| Support Level | $75.19 | $82.43 |
| Resistance Level | N/A | $100.69 |
| Average True Range (ATR) | 4.47 | 4.35 |
| MACD | -0.14 | 0.96 |
| Stochastic Oscillator | 68.84 | 80.90 |
Price Performance
Historical ComparisonAbout CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable operating segments of the company are the Crocs Brand and the HEYDUDE Brand. The company derives maximum revenue from the Crocs brand segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.